Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Definity-Enhanced Ultrasound for Focal Liver Lesion Detection
NCT00162058Phase 2Completed
- Sponsor
- Lantheus Holdings, Inc.
- Start
- Mar 2004
- Primary completion
- Apr 2006
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of perflutren lipid microspheres in focal liver lesions (FLLs), sponsored by Lantheus Holdings, Inc. Primary endpoint: Ratio of signal intensities obtained from unenhanced vs. contrast-enhanced ultrasound imaging. Started Mar 2004; status: completed.
02
Drugs
perflutren lipid microspheres
03
Conditions
focal liver lesions (FLLs)
Beyond the preview
Go deeper on NCT00162058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00162058.